The United States of America, As Represented by the Secretary, Department of Health and Human Services

Sanofi

Jinghe Huang

Mark Connors

John R Mascola

Peter D Kwong

Gary J Nabel

Huawei Qiu

Leo Laub

Baoshan Zhang

Yongping Yang

Tongqing Zhou

Ercole Rao

Christian Lange

Ivelin Georgiev

Jochen Kruip

Gilad Ofek

John Mascola

Young Do Kwon

Christian Beil

Ling Xu

Zhi-Yong Yang

Jochen Beninga

Wulf Dirk Leuschner

Jiang Zhu

Rebecca S Rudicell

Anqi Zheng

Elise Ishida

Byong Ha Kang

Nicole Amy Doria-Rose

Mangaiarkarasi Asokan

Amarendra Pegu

Nancy Longo

Richard A Koup

Nicole A Doria-rose

Ronnie Wei

Leo B Laub

Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

Neutralizing antibodies to GP120 and their use

Neutralizing antibodies to gp120 and their use

Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.

Neutralizing GP41 antibodies and their use

Growing community of inventors

Bethesda, MD, United States of America

Jinghe Huang